A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Bibliographic Details
Main Authors: Leijen, Suzanne, Soetekouw, Patricia M. M. B., Jeffry Evans, T. R., Nicolson, Marianne, Schellens, Jan H. M., Learoyd, Maria, Grinsted, Lynda, Zazulina, Victoria, Pwint, Thinn, Middleton, Mark
Format: Online
Language:English
Published: Springer-Verlag 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220813/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220813/

Similar Items